65min, daily, weekly for stocks
2-3D for crypto-currencies and pairs
the only frame guidance you need based on my experience
repeating it from time to time so you know this
Shares of Viking Therapeutics fell as much as 37% after Phase 2 VENTURE-Oral trial results for its oral obesity drug, while LLY rose 1.5% on perceived competitive advantages.
Viking’s oral tablet VK2735, a dual GLP-1/GIP agonist, met its primary endpoint with up to 12.2% weight loss after 13 weeks vs. 1.3% for placebo. However, a 28% discontinuation rate vs. 18% for placebo raised concerns.
Mizuho’s Jared Holz ($8411.T) said results look weaker than LLY across metrics, noting LLY showed ~20% dropout over 72 weeks, making it more favorable. Holz argued VKTX likely won’t be a major near-term player in oral obesity drugs, adding that stronger pipelines or better formulations are needed.
$VKTX $LLY
@satymahajan Hey Saty, I’m a great fan of your work. I tried to set up your pivot ribbon and ATR on TOS as you suggested in Satyland but mine still doesn’t look like yours in this pic. Can you help me how can I set up my TOS to exactly look like yours including the candle colors. Thanks.
@dreyonthemoon Thank you. I follow your posts regularly. Thanks for all the great education. My goal is to quit 1 of my 2 my jobs and become a trader like you in future.